ABBVON

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

심볼ABBVON

순위No.3167

시가총액$0.00

완전히 희석된 시가총액$0.00

시장 점유율%

거래량/시가총액 (24시간)632,672.50%

유통 공급량221.99426815

최대 공급량0

총 공급량221.99426815

유통률%

발행일--

자산이 처음 발행된 가격--

사상 최고가230.6290690824876,2026-02-02

최저가207.47261007076094,2026-02-04

퍼블릭 블록체인ETH

소개AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

섹터

SNS

• 공식 웹사이트
• 블록 탐색기

etfindex:mc_etfindex_source면책 조항: cmc에서 제공한 데이터는 투자 조언으로 간주되어서는 안 됩니다.